Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01470924
Recruitment Status : Completed
First Posted : November 11, 2011
Last Update Posted : November 11, 2011
Information provided by (Responsible Party):
Piotr Kozlowski, Region Örebro County

Brief Summary:
A minority of patients with adult acute lymphoblastic leukemia (ALL) relapse are rescued. The aim of this population-based study was to assess the results of reinduction treatment and allogeneic stem cell transplantation (SCT) in second complete remission (CR) in Sweden 2003-2007.

Condition or disease
Acute Lymphoblastic Leukemia

Detailed Description:
This is a national, multicenter, prospective, population-based study of outcome among adult patients aged 19 to 65 years with ALL relapse diagnosed during 2003-2007 in Sweden. Most of the patients had primary treatment according to National guidelines for ALL as recommended by The Swedish Adult ALL Group (SVALL). The guidelines suggest two different treatment protocols for early relapses, and retreatment according to the initial therapy for late relapses, with the intention to proceed to allogeneic SCT in CR2 for eligible patients. The aim of the current study was to assess outcome among adult patients after first ALL relapse, and the utilization and efficacy of recommended protocols and of allogeneic SCT in this setting.

Study Type : Observational
Actual Enrollment : 76 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: High Curability Via Intensive Reinduction Chemotherapy and Stem Cell Transplantation in Young Adults With Relapsed Acute Lymphoblastic Leukemia in Sweden 2003-2007
Study Start Date : January 2003
Actual Study Completion Date : June 2011

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 66 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
All adults with relapsed ALL

Inclusion Criteria:

  • Adult patients with first relapse of ALL

Exclusion Criteria:

  • patients with Burkitt leukemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01470924

Orebro University Hospital
Orebro, Orebro County, Sweden, 70185
Sponsors and Collaborators
Region Örebro County
Principal Investigator: Piotr J Kozlowski, MD Region Örebro County

Responsible Party: Piotr Kozlowski, Principal Investigator, Region Örebro County Identifier: NCT01470924     History of Changes
Other Study ID Numbers: OLL-180361
First Posted: November 11, 2011    Key Record Dates
Last Update Posted: November 11, 2011
Last Verified: November 2011

Keywords provided by Piotr Kozlowski, Region Örebro County:
acute lymphoblastic leukemia

Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases